Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice

Pharmacology Biochemistry and Behavior

Volumn 98, Issue 2, 2011, Pages 286-291

  Mu, Xin ^a   He, Guo Rong ^a   Yuan, Xia ^b   Li, Xiao Xiu ^a   Du, Guan Hua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

1 Methyl 4 phenyl 1,2,3; 6 tetrahydropyridine; Antioxidant; Baicalein; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 METHYLENEDIOXYAMPHETAMINE; BAICALEIN; DOPAMINE; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; C57BL 6 MOUSE; CATECHOLAMINE DEPLETION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; FUNCTIONAL MORPHOLOGY; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; ROTAROD TEST; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; CORPUS STRIATUM; DOPAMINE; FLAVANONES; GLUTATHIONE PEROXIDASE; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; OXIDATIVE STRESS; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 79751527791     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.01.011     Document Type: Article

References (24)

1. R. Betarbet, T.B. Sherer, and J.T. Greenamyre Animal models of Parkinsons disease Bioessays 24 2002 308 318
2. S.F. Chen, C.W. Hsu, W.H. Huang, and J.Y. Wang Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury Br J Pharmacol 155 2008 1279 1296
3. Y. Cheng, G. He, X. Mu, T. Zhang, X. Li, and J. Hu Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile Neurosci Lett 441 2008 16 20
4. + Free Rad Biol Med 13 1992 581 583
5. L. Cui, X. Zhang, R. Yang, L. Liu, L. Wang, and M. Li Baicalein is neuroprotective in rat MCAO model: role of 12/15-lipoxygenase, mitogen-activated protein kinase and cytosolic phospholipase A2 Pharmacol Biochem Behav 96 2010 469 475
6. J.D. Grimes, M.N. Hassan, and J.H. Thakar Prevention of progression of Parkinsons disease with antioxidative therapy Prog Neuropsychopharmacol Biol Psychiatry 12 1988 165 172
7. R.E. Heikkila, A. Hess, and R.C. Duvoisin Dopaminergic neurotoxicity of 1-methyl-4- phenyl-1, 2, 5, 6-tetrahydropyridine in mice Science 224 1984 1451 1453 (Pubitemid 14123348)
8. H.I. Im, W.S. Joo, E. Nam, E.S. Lee, Y.J. Hwang, and Y.S. Kim Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice J Pharmacol Sci 98 2005 185 189 (Pubitemid 40943726)
9. P. Jenner Oxidative stress in Parkinsons disease Ann Neurol 53 2003 26 36
10. F.Q. Li, T. Wang, Z. Pei, B. Liu, and J.S. Hong Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons J Neural Transm 112 2005 331 347 (Pubitemid 40868048)
11. J. Lotharius, and K.L. OMalley The parkinsonism-inducing drug 1-methyl-4- phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity J Biol Chem 275 2000 38581 38588 (Pubitemid 32009186)
12. S. Mandel, and M.B. Youdim Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases Free Radic Biol Med 37 2004 304 317 (Pubitemid 38833997)
13. G.E. Meredith, S. Totterdell, J.A. Potashkin, and D.J. Surmeier Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol Parkinsonism Relat Disord 14 2008 112 115
14. X. Mu, G. He, Y. Cheng, X. Li, B. Xu, and G. Du Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro Pharmacol Biochem Behav 92 2009 642 648
15. J.A. Obeso, M.C. Rodriguez-Oroz, M. Rodriguez, J.L. Lanciego, J. Artieda, and N. Gonzalo Pathophysiology of the basal ganglia in Parkinsons disease Trends Neurosci 23 2000 8 19
16. C.W. Olanow, and W.C. Koller An algorithm (decision tree) for the management of Parkinsons disease: treatment guidelines American Academy of Neurology. Neurology 50 1998 S1 S57
17. S. Przedborski, and M. Vila The 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinsons disease Annals of the New York Academy of Sciences 991 2003 189 198 (Pubitemid 36793814)
18. N. Schmidt, and B. Ferger Neurochemical findings in the MPTP model of Parkinsons disease J Neural Transm 108 2001 1263 1282 (Pubitemid 33141302)
19. A. Schober Classic toxin-induced animal models of Parkinsons disease: 6-OHDA and MPTP Cell Tissue Res 318 2004 215 224 (Pubitemid 39366054)
20. E. Sundstrom, A. Fredriksson, and T. Archer Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinsons disease Brain Res 528 1990 181 188 (Pubitemid 20318194)
21. J.A. Wu, A.S. Attele, L. Zhang, and C.S. Yuan Anti-HIV activity of medicinal herbs: usage and potential development Am J Chin Med 29 2001 69 81 (Pubitemid 33775399)
22. H. Yuan, J.C. Zheng, P. Liu, S.F. Zhang, J.Y. Xu, and L.M. Bai Pathogenesis of Parkinsons disease: oxidative stress, environmental impact factors and inflammatory processes Neurosci Bull 23 2007 125 130 (Pubitemid 46797510)
23. B. Zhao Natural antioxidants protect neurons in Alzheimers disease and Parkinsons disease Neurochem Res 34 2009 630 638
24. M.J. Zigmond, and E.M. Stricker Animal models of parkinsonism using selective neurotoxins: clinical and basic implications Int Rev Neurobiol 31 1989 1 79